Related Experiment Video
Updated: Jul 18, 2026

Genetic Manipulation in Δku80 Strains for Functional Genomic Analysis of Toxoplasma gondii
Published on: July 12, 2013
Genetic background influences UPR but not PLP processing in the rumpshaker model of PMD/SPG2
M McLaughlin1, S A Karim, P Montague
1Applied Neurobiology Group, Division of Cell Sciences, Institute of Comparative Medicine, University of Glasgow, Bearsden, Glasgow, G61 1QH, Scotland.
Abstract:
Mutations of the proteolipid protein gene (PLP1) cause Pelizaeus-Merzbacher disease (PMD) and Spastic paraplegia type 2 (SPG2). The rumpshaker mutation is associated with mild forms of PMD or SPG2 in man and the identical mutation occurs in mice, the phenotype depending on genetic background. The mild phenotype in C3H mice becomes a lethal disease when expressed on the C57BL/6 background. rumpshaker PLP is synthesised at a similar rate to wild type but is rapidly degraded by the proteasome. We show that the rates of synthesis, degradation and myelin incorporation of PLP/DM20 are similar in mutants on both backgrounds and therefore differences in PLP processing are unlikely to be the basis of the phenotypic variation. An unfolded protein response (UPR) is activated in rumpshaker. Whereas activation of CHOP correlates with phenotypic severity, we find no difference in the response of BiP and X-box protein1 (Xbp1) between the two strains.
Insights
Genetic background significantly impacts the severity of Pelizaeus-Merzbacher disease (PMD) in mice with the rumpshaker mutation. Protein processing differences do not explain this phenotypic variation, suggesting other factors influence disease progression.
Area of Science:
- Neuroscience
- Genetics
- Cell Biology
Background:
- Mutations in the proteolipid protein gene (PLP1) are linked to Pelizaeus-Merzbacher disease (PMD) and Spastic paraplegia type 2 (SPG2).
- The rumpshaker mutation in PLP1 causes milder forms of these neurological disorders in humans and mice.
Purpose of the Study:
- To investigate the molecular mechanisms underlying the variable phenotypic severity of the rumpshaker mutation in different mouse genetic backgrounds.
- To determine if differences in proteolipid protein (PLP) processing or unfolded protein response (UPR) pathways contribute to the observed phenotypic variation.
Main Methods:
- Comparative analysis of PLP/DM20 synthesis, degradation, and myelin incorporation rates in C3H and C57BL/6 mice carrying the rumpshaker mutation.
- Assessment of unfolded protein response (UPR) activation, including the expression of CHOP, BiP, and Xbp1, in relation to phenotypic severity.
Main Results:
- The rumpshaker mutation leads to a lethal phenotype in C57BL/6 mice, contrasting with a milder form in C3H mice, despite similar PLP/DM20 synthesis, degradation, and myelin incorporation rates across both backgrounds.
- An unfolded protein response (UPR) is activated in rumpshaker mutants, with CHOP activation correlating with disease severity.
- No significant differences were observed in the activation of BiP and X-box protein1 (Xbp1) between the two mouse strains, suggesting these specific UPR components are not primary drivers of the phenotypic variation.
Conclusions:
- Phenotypic variation in rumpshaker-associated neurological disorders is not solely due to differences in PLP/DM20 protein processing.
- The severity of the disease phenotype is linked to the activation of specific components of the unfolded protein response (UPR), such as CHOP.
- The genetic background plays a critical role in modulating the impact of PLP1 mutations on disease outcome.
More Related Videos
08:09Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
Published on: January 7, 2014
08:22A Novel Strategy Combining Array-CGH, Whole-exome Sequencing and In Utero Electroporation in Rodents to Identify Causative Genes for Brain Malformations
Published on: December 1, 2017
Related Concept Videos
Position-effect Variegation
Chromatin Structure Regulates pre-mRNA Processing
The chromatin structure, especially...
Principles of Pharmacogenetics: Types of Genetic Variants